Waters Corporation and Dotmatics Limited have announced an agreement to develop an integrated advanced metabolism elucidation tool which will complement Waters time-of-flight mass spectrometry products and, in particular, the Waters Xevo MS and SYNAPT G2 products. The agreement will focus on developing a fully integrated solution for metabolism elucidation between the Dotmatics and Waters MassLynx informatics platform that will provide scientists the capability to identify the nature and site of metabolism of a candidate pharmaceutical compound, allowing them to accelerate optimization in drug discovery.
“We are very pleased to offer this software tool to drug discovery labs, reducing their bottlenecks in deciphering metabolic transformations,” said Tim Riley, Vice President, Pharmaceutical Business Operations for the Waters Division. “This software leverages the comprehensive data implicit to our innovative UPLC/MSE data acquisition strategies. Together with Waters ACQUITY UPLC, Xevo QTof MS or the new SYNAPT G2 HDMS system, the informatics tools evolving from this collaboration provide researchers with the most advanced and productive workflow for characterizing small molecule metabolism.”
“We are delighted to be continuing our collaboration with Waters Corporation,” said Mike Hartshorn, Director and CSO at Dotmatics. ”Through this agreement we will be able to deliver cutting-edge MS analysis software to scientists across the drug discovery industry.”
Waters introduced the Synapt G2 System and exhibited its latest technologies at the 57th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics in Philadelphia, PA.
Date: June 1, 2009
Source: Waters Corporation
Filed Under: Drug Discovery
